KCNT1 related epilepsy is a genetic seizure disorder caused by a mutation in the KCNT1 gene. The most common symptoms are seizures and developmental delay. The two most common phenotypes are Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) and Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE). Less common seizure phenotypes include West syndrome, Ohtahara syndrome, early myoclonic encephalopathy, leukodystrophy, focal epilepsy, multifocal epilepsy. The seizures can begin within the first month of life or later into childhood. In the EIMFS syndrome, these seizures can arise on one part of the brain and move to the other and lead to further neurological damage or halt development. Other symptoms can include cortical visual Impairment, neuroirritability, gastroesophageal reflux, constipation, neurogenic bladder, hip dysplasia, hypotonia, and dystonia. Some children develop pulmonary collaterals and cardiac arrhythmias which increase the risk of mortality. Children are also at risk for sudden unexpected death in epilepsy (SUDEP). The ADNFLE syndrome typically arises after six months and can have less seizures than EIMFS, most of which occur during sleep and can look like sleep terrors. These children may be typically developing but may have autistic-like behaviors, attention deficit disorder (ADD), ADHD, or other psychological difficulties. The prevalence of KCNT1-related epilepsy is unknown. At least 200 cases have been identified worldwide. There are no FDA-approved therapies for KCNT1-related epilepsy. Seizures are treated with conventional anticonvulsant medications, but most patients show minimal improvement. Ketogenic diet is occasionally helpful in reducing seizure burden. Quinidine has been used as an off-label anticonvulsant with success in some individuals. KCNT1 is diagnosed with genetic testing of the KCNT1 gene. Although there is currently no cure for KNCT1 epilepsy, various resources to help manage the condition and treat the symptoms.